178 related articles for article (PubMed ID: 1984710)
21. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients.
van Laar MW; Volkerts ER; van Willigenburg AP
J Clin Psychopharmacol; 1992 Apr; 12(2):86-95. PubMed ID: 1573045
[TBL] [Abstract][Full Text] [Related]
22. Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy.
Udelman HD; Udelman DL
J Clin Psychiatry; 1990 Sep; 51 Suppl():46-50. PubMed ID: 2211568
[TBL] [Abstract][Full Text] [Related]
23. Alprazolam in young and elderly men: sensitivity and tolerance to psychomotor, sedative and memory effects.
Bertz RJ; Kroboth PD; Kroboth FJ; Reynolds IJ; Salek F; Wright CE; Smith RB
J Pharmacol Exp Ther; 1997 Jun; 281(3):1317-29. PubMed ID: 9190868
[TBL] [Abstract][Full Text] [Related]
24. Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans.
Busto U; Kaplan HL; Zawertailo L; Sellers EM
Clin Pharmacol Ther; 1994 Apr; 55(4):451-63. PubMed ID: 8162672
[TBL] [Abstract][Full Text] [Related]
25. Effects of buspirone and alprazolam treatment on the startle-potentiated startle response.
Commissaris RL; Fomum EA; Leavell BJ
Depress Anxiety; 2004; 19(3):146-51. PubMed ID: 15129416
[TBL] [Abstract][Full Text] [Related]
26. Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects.
Mumford GK; Rush CR; Griffiths RR
J Pharmacol Exp Ther; 1995 Feb; 272(2):570-80. PubMed ID: 7853170
[TBL] [Abstract][Full Text] [Related]
27. Effects of single oral doses of bromazepam, buspirone and clobazam on performance tasks and memory.
Bourin M; Auget JL; Colombel MC; Larousse C
Neuropsychobiology; 1989; 22(3):141-5. PubMed ID: 2577220
[TBL] [Abstract][Full Text] [Related]
28. Alprazolam 0.125 mg twice a day improves aspects of psychometric performance in healthy volunteers.
Bourin M; Colombel MC; Guitton B
J Clin Psychopharmacol; 1998 Oct; 18(5):364-72. PubMed ID: 9790153
[TBL] [Abstract][Full Text] [Related]
29. Comparison of acute alprazolam (0.25, 0.50 and 1.0 mg) effects versus those of lorazepam 2 mg and placebo on memory in healthy volunteers using laboratory and telephone tests.
Vermeeren A; Jackson JL; Muntjewerff ND; Quint PJ; Harrison EM; O'Hanlon JF
Psychopharmacology (Berl); 1995 Mar; 118(1):1-9. PubMed ID: 7597114
[TBL] [Abstract][Full Text] [Related]
30. Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers.
Allain H; Tessier C; Bentué-Ferrer D; Tarral A; Le Breton S; Gandon M; Bouhours P
Psychopharmacology (Berl); 2003 Feb; 165(4):419-29. PubMed ID: 12459926
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of cognitive function in healthy older subjects treated with fesoterodine.
Kay GG; Maruff P; Scholfield D; Malhotra B; Whelan L; Darekar A; Martire DL
Postgrad Med; 2012 May; 124(3):7-15. PubMed ID: 22691894
[TBL] [Abstract][Full Text] [Related]
32. Behavioral effects of alprazolam in humans.
Kelly TH; Foltin RW; Serpick E; Fischman MW
Behav Pharmacol; 1997 Feb; 8(1):47-57. PubMed ID: 9833000
[TBL] [Abstract][Full Text] [Related]
33. A statistical approach for classifying change in cognitive function in individuals following pharmacologic challenge: an example with alprazolam.
Maruff P; Werth J; Giordani B; Caveney AF; Feltner D; Snyder PJ
Psychopharmacology (Berl); 2006 May; 186(1):7-17. PubMed ID: 16572266
[TBL] [Abstract][Full Text] [Related]
34. Comparative study of the psychomotor and antistress effects of ritanserin, alprazolam and diazepam in healthy subjects: some trait anxiety-independent responses.
Danjou P; Warot D; Hergueta T; Lacomblez L; Bouhours P; Puech AJ
Int Clin Psychopharmacol; 1992 Nov; 7(2):73-9. PubMed ID: 1487624
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of alprazolam on the baseline and fear-potentiated startle reflex in humans: a dose-response study.
Riba J; Rodríguez-Fornells A; Urbano G; Morte A; Antonijoan R; Barbanoj MJ
Psychopharmacology (Berl); 2001 Oct; 157(4):358-67. PubMed ID: 11605094
[TBL] [Abstract][Full Text] [Related]
36. The acute and chronic performance effects of alprazolam and lorazepam in the elderly: relationship to duration of treatment and self-rated sedation.
Pomara N; Tun H; DaSilva D; Hernando R; Deptula D; Greenblatt DJ
Psychopharmacol Bull; 1998; 34(2):139-53. PubMed ID: 9640992
[TBL] [Abstract][Full Text] [Related]
37. Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies.
Greenblatt DJ; Harmatz JS; Gouthro TA; Locke J; Shader RI
Clin Pharmacol Ther; 1994 Jul; 56(1):100-11. PubMed ID: 8033487
[TBL] [Abstract][Full Text] [Related]
38. Comparative drug effects and abuse liability of lorazepam, buspirone, and secobarbital in nondependent subjects.
Sellers EM; Schneiderman JF; Romach MK; Kaplan HL; Somer GR
J Clin Psychopharmacol; 1992 Apr; 12(2):79-85. PubMed ID: 1573044
[TBL] [Abstract][Full Text] [Related]
39. Amnestic and anxiolytic effects of alprazolam in oral surgery patients.
Coldwell SE; Milgrom P; Getz T; Ramsay DS
J Oral Maxillofac Surg; 1997 Oct; 55(10):1061-70. PubMed ID: 9331228
[TBL] [Abstract][Full Text] [Related]
40. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder.
Enkelmann R
Psychopharmacology (Berl); 1991; 105(3):428-32. PubMed ID: 1798836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
